State Street’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $271M | Buy |
3,057,416
+450,385
| +17% | +$32.9M | 0.01% | 871 |
|
|
2026
Q1 | $131M | Buy |
2,607,031
+344,192
| +15% | +$13M | ﹤0.01% | 1214 |
|
|
2025
Q4 | $74.1M | Buy |
2,262,839
+477,633
| +27% | +$12.5M | ﹤0.01% | 1515 |
|
|
2025
Q3 | $29.9M | Buy |
1,785,206
+189,915
| +12% | +$3.1M | ﹤0.01% | 2014 |
|
|
2025
Q2 | $23.9M | Sell |
1,595,291
-101,824
| -6% | -$1.51M | ﹤0.01% | 2093 |
|
|
2025
Q1 | $27.4M | Buy |
1,697,115
+16,179
| +1% | +$337K | ﹤0.01% | 1958 |
|
|
2024
Q4 | $39.1M | Buy |
1,680,936
+139,381
| +9% | +$4.09M | ﹤0.01% | 1846 |
|
|
2024
Q3 | $45.3M | Buy |
1,541,555
+131,896
| +9% | +$3.67M | ﹤0.01% | 1753 |
|
|
2024
Q2 | $33.1M | Buy |
1,409,659
+1,275,233
| +949% | +$43M | ﹤0.01% | 1868 |
|
|
2024
Q1 | $5.1M | Buy |
+134,426
| New | +$3.89M | ﹤0.01% | 2916 |
|
|
2023
Q3 | – | Sell |
-7,804
| Closed | -$87.9K | – | 4588 |
|
|
2023
Q2 | $87.9K | Sell |
7,804
-796
| -9% | -$3.77K | ﹤0.01% | 4274 |
|
|
2023
Q1 | $62.3K | Hold |
8,600
| – | – | ﹤0.01% | 4449 |
|
|
2022
Q4 | $96.7K | Buy |
8,600
+2,240
| +35% | +$40.3K | ﹤0.01% | 4376 |
|
|
2022
Q3 | $84K | Hold |
6,360
| – | – | ﹤0.01% | 4524 |
|
|
2022
Q2 | $80K | Sell |
6,360
-25,122
| -80% | -$880K | ﹤0.01% | 4606 |
|
|
2022
Q1 | $1.81M | Buy |
31,482
+1,160
| +4% | +$97.4K | ﹤0.01% | 3605 |
|
|
2021
Q4 | $3.6M | Sell |
30,322
-356
| -1% | -$56.2K | ﹤0.01% | 3398 |
|
|
2021
Q3 | $6.1M | Buy |
30,678
+378
| +1% | +$66.1K | ﹤0.01% | 3127 |
|
|
2021
Q2 | $5.27M | Buy |
30,300
+1,561
| +5% | +$284K | ﹤0.01% | 3223 |
|
|
2021
Q1 | $5.69M | Sell |
28,739
-354
| -1% | -$67.9K | ﹤0.01% | 3001 |
|
|
2020
Q4 | $5.72M | Buy |
29,093
+2,819
| +11% | +$584K | ﹤0.01% | 2897 |
|
|
2020
Q3 | $4.66M | Buy |
26,274
+162
| +0.6% | +$30K | ﹤0.01% | 2820 |
|
|
2020
Q2 | $6.04M | Buy |
26,112
+7,244
| +38% | +$1.38M | ﹤0.01% | 2663 |
|
|
2020
Q1 | $2.2M | Buy |
18,868
+276
| +1% | +$46.9K | ﹤0.01% | 3028 |
|
|
2019
Q4 | $3.55M | Buy |
18,592
+1,324
| +8% | +$260K | ﹤0.01% | 3014 |
|
|
2019
Q3 | $3.32M | Buy |
17,268
+1,897
| +12% | +$369K | ﹤0.01% | 2996 |
|
|
2019
Q2 | $2.63M | Buy |
15,371
+5,570
| +57% | +$963K | ﹤0.01% | 3131 |
|
|
2019
Q1 | $1.97M | Sell |
9,801
-41
| -0.4% | -$8.55K | ﹤0.01% | 3153 |
|
|
2018
Q4 | $1.84M | Sell |
9,842
-98
| -1% | -$20.8K | ﹤0.01% | 3153 |
|
|
2018
Q3 | $2.38M | Buy |
9,940
+999
| +11% | +$233K | ﹤0.01% | 3187 |
|
|
2018
Q2 | $2.37M | Buy |
+8,941
| New | +$2.2M | ﹤0.01% | 3185 |
|
Other funds holding SYRE
PA
RI
PBA
VA
DCM
State Street's SYRE Position: Q2 2026 in Review
State Street increased its Spyre Therapeutics (SYRE) stake by 17% in Q2 2026, buying an estimated $32.9M and bringing the position to 3,057,416 shares worth $271M. The position accounts for 0.01% of the portfolio, ranked #871.
State Street first reported a position in SYRE in Q2 2018 and has held it in 31 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.
- State Street held 3,057,416 shares of Spyre Therapeutics worth $271M as of Q2 2026.
- State Street bought 450,385 Spyre Therapeutics shares in Q2 2026, an estimated $32.9M.
- Spyre Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #871 holding.
- State Street first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 31 quarters since.
- 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.